Volume 26, Issue 1 (4-2024)                   yafte 2024, 26(1): 73-84 | Back to browse issues page


XML Persian Abstract Print


Aligudarz School of Nursing, Lorestam University of Medical Sciences, Khorram Abad, Iran & Aligudarz School of Nursing, Lorestam University of Medical Sciences, Khorram Abad, Iran
Abstract:   (3365 Views)
Background: COVID-19 was a global epidemic that led to numerous problems, including menstrual disorders in women. The present study aimed to assess the frequency of menstrual disorders and related factors in women with COVID-19.
Materials and Methods: The descriptive study was conducted on 80 women with COVID-19 in the first six months of 2022. Information was collected using a telephone questionnaire and data analysis was performed in SPSS software (version 16) using descriptive statistics (frequency and percentage) and analysis (chi-square and independent t-test).
Results: Based on the results, 43.7% of women had menstrual disorders during the COVID-19 pandemic. Among these women, 26.3% and 17.5% of cases considered the disorder to be related to receiving the COVID-19 vaccine and COVID-19 infection, respectively. Massive bleeding (17.5%) and low-volume bleeding (7.5%) were the most reported disorders, and Sinopharm (76.3%) and AstraZeneca (15.0%) vaccines were the most used vaccines. The results of statistical tests did not demonstrate a significant relationship between the presence of disorder and other variables (P>0.05).
Conclusion: Menstrual disorders increased during COVID-19 compared to before. Considering the resolution of this disorder after several months, it is recommended that if the disorder is not resolved, it should be referred for identification and follow-up in time to reduce the dangerous consequences of women's diseases.
 
Full-Text [PDF 346 kb]   (1752 Downloads)    
Type of Study: Original Research | Subject: زنان
Received: 2024/01/4 | Accepted: 2024/05/14 | Published: 2024/04/29

Rights and permissions
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.